Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
varicella virus vaccine live (1999 process)
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Varicella virus vaccine live (1999 process) is a live attenuated virus vaccine derived from the Oka strain of the varicella-zoster virus (VZV). Developed by Merck, this specific "1999 process" version refers to a manufacturing modification approved by the FDA to optimize the production, potency, and stability of the vaccine, marketed under the brand name Varivax. It is indicated for active immunization to prevent chickenpox in individuals aged 12 months and older. The vaccine works by mimicking a natural infection to elicit a protective immune response, including both humoral (antibody) and cell-mediated immunity, without causing significant disease in healthy individuals. The 1999 process was a critical regulatory milestone that ensured consistent manufacturing standards for the first varicella vaccine approved in the United States.
- Brand names
- Varivax
- Other names
- varicella virus vaccine live (1999 process)Oka/Merck varicella vaccinevaricella vaccine livevaricella vaccine
Beyond the preview
Go deeper on varicella virus vaccine live (1999 process).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on varicella virus vaccine live (1999 process).